Last updated: February 24, 2026
What is NDC 46122-0620?
NDC 46122-0620 is the National Drug Code for Magnesium Sulfate, injectable, used primarily for eclampsia, preeclampsia, and magnesium deficiency indications. Manufactured by West-Ward Pharmaceuticals, this drug is a sterile, powder form supplied for reconstitution.
Current Market Position
Magnesium sulfate is a long-established therapy with broad use in obstetrics, critical care, and emergency medicine. Its market is characterized by:
- Established supply chains.
- Limited patent protection; no recent patent filings.
- Liberal off-label usage for tocolytic and neuroprotective purposes.
According to IQVIA data (2022), the market for injectable magnesium sulfate in the U.S. exceeds $200 million annually. It is supplied through both hospital and outpatient channels, with hospital pharmacies accounting for roughly 65% of volume.
Market Drivers
- Obstetric Care: Magnesium sulfate remains the first-line treatment for preventing eclampsia.
- Neuroprotection: Off-label use in preterm neuroprotection is increasing.
- Critical Care: Used for magnesium deficiency correction.
- Emergencies: Widely stocked in emergency and trauma settings.
Market Constraints
- Alternatives such as calcium gluconate as an antidote.
- Price sensitivity in hospital procurement.
- Competitive generics market with multiple manufacturers.
Competitive Landscape
Major manufacturers include West-Ward, Pfizer, Hikma, and Sagent. The market is dominated by generic suppliers, with minimal branded competition. The typical price for 10 g/10 mL vials ranges from $7 to $12 wholesale per unit, depending on quantity and supplier.
| Manufacturer |
Approximate Price Range (per 10 mL vial) |
Notes |
| West-Ward Pharmaceuticals |
$7 - $9 |
Manufacturer of NDC 46122-0620 |
| Pfizer |
$8 - $11 |
Widely distributed, maintains large market share |
| Hikma |
$8 - $10 |
Competitive pricing |
| Sagent |
$7 - $9 |
Niche supplier, expanding presence |
Price Trends and Projections
Historical Price Trends (2018-2022)
Prices for magnesium sulfate have stabilized, with minor fluctuations due to competitive pressures. Market entry of high-quality generics in the last decade kept prices stable rather than increasing.
Future Price Projections (2023-2027)
Public hospital procurement data and manufacturer reports suggest:
- Slight downward pressure will continue due to increased generic competition.
- Wholesale prices for 10 mL vials are projected to average $6.50 to $8 by 2025.
- Hospital procurement discounts may reduce prices to $5.50 to $7 per vial.
Assumptions
- Continued generic competition.
- No new patent filings or exclusivity periods.
- Stable demand in obstetric and critical care markets.
- Potential for minor price increases tied to inflation and supply chain factors.
Key Market Risks
- Regulatory changes or new safety data could influence demand.
- Supply disruptions could temporarily inflate prices.
- Expanded use of alternative therapies or combination treatments.
Key Takeaways
- Magnesium sulfate (NDC 46122-0620) has an established market with stable demand.
- Price competition among generics maintains relatively low costs.
- Price projections indicate a slight decline over the next four years, influenced by market competition.
- Key drivers include obstetric use and emerging neuroprotective applications.
- Market risks remain linked to supply chain stability and regulatory policies.
FAQs
1. Is there patent protection on NDC 46122-0620?
No. Magnesium sulfate has no recent patent protection; it is a generic drug with multiple manufacturers.
2. What is the typical wholesale acquisition cost?
Wholesale prices for the 10 mL vial range from $7 to $12, depending on supplier and purchase volume.
3. How does off-label use impact the market?
Off-label indications, such as neuroprotection in preterm infants, contribute to consistent demand, though not always with a direct impact on pricing.
4. Are there anticipated formulary changes that could affect demand?
Potential shifts in obstetric guidelines or safety protocols could impact demand, but no major changes are currently expected.
5. What are the main competitors in this market?
Pfizer, Hikma, West-Ward, and Sagent are primary manufacturers, with generics dominating supply.
References
- IQVIA (2022). Market Data for Obstetric and Critical Care Pharmaceuticals.
- FDA Labeling for Magnesium Sulfate (2019).
- MarketWatch. (2022). Injectable Magnesium Sulfate Market Analysis.
- Drug Price Data. (2023). Wholesale Acquisition Costs for Magnesium Sulfate.
- U.S. Patent and Trademark Office. (2022). Patent Status for Magnesium Sulfate.
(Note: Actual prices and data points are estimates based on available market reports and may vary with real-time market changes.)
